drugset / Trial / NCT00988065

Sugammadex Hypersensitivity Study (Study P06042)

NCT00988065

Phase 1 Completed 448 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was conducted to study the potential for hypersensitivity symptoms at the time of initial exposure to sugammadex and upon repeat exposure, since it was unknown whether the frequency or severity of hypersensitivity symptoms may worsen at repeat exposure over a prolonged period. In total 450 participants (all healthy subjects) were to be randomized to receive one of three study treatments: three repeated doses of either sugammadex 4 mg/kg, sugammadex 16 mg/kg, or placebo. Participants were to receive one dose of study treatment on Day 8, Day 36, and Day 78 of the study in order to determine the safety of each treatment dose.

Timeline

Start
2009-09-06
Primary completion
2010-04-13
Completion
2010-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Sugammadex Other / unclassified 4 mg/kg Intravenous
Subject Sugammadex Other / unclassified 16 mg/kg Intravenous